Ruggell, Liechtenstein, 24 January 2012- Pantec Biosolutions AG, the developer and manufacturer of P.L.E.A.S.E.® Professional, a state of the art portable laser device that sets new standards for safety, precision and versatility, today announced that it will be giving a scientific company presentation during the “Drug Delivery Partnerships” conference from 25th -27th January 2012 in Las Vegas, USA.
Sven Rohmann, M.D. PhD, Pantec Biosolutions’ CBO, will be presenting on the exact science that makes P.L.E.A.S.E.® Professional unique as well as the advantages of the innovative laser device and its multiple application areas.
The presentation will be held at 3:15 PM on 26th January 2012.
Pantec Biosolutions AG has developed and commercialised a laser-powered skin microporation method (P.L.E.A.S.E.® - Precise Laser EpidermAl SystEm) for use prior to drug patch application, which extends the range of drugs that can be delivered transdermally to large molecular weight drugs. This novel application allows the drugs to be delivered directly into the epidermis in a dose-controlled manner, thus avoiding painful injections.
The Company's first focus is to replace the approximately one hundred injections typically applied during hormone therapy in In Vitro Fertilisation (IVF). Drug patch development for IVF hormones is underway and the Company intends to commercialise their product solution "P.L.E.A.S.E.® - device plus drug patches" with a pharma partner company. Further interesting therapeutic areas are currently in preclinical development.
The recently launched P.L.E.A.S.E.® Professional device fulfils the highest safety standards of a medical device and offers ultimate precision, enabling microporation of the skin for the transdermal delivery of large molecule proteins (e.g. hormones for IVF treatment and biopharmaceuticals). P.L.E.A.S.E.® Professional is currently marketed in the European Union as a device for SMART PORATION™ Therapy and other micro-poration based bio-active agent delivery therapies in dermatology and aesthetic medicine.
For more information, please visit: www.please-professional.com
“Drug Delivery Partnerships” is a conference focused on the discovery of innovative products to anticipate and take advantage of trends in the partnering landscape and implement the best practices to ensure your company stays ahead of the curve.
For a detailed agenda, please follow the link to the conference homepage.
|For further information, please contact Pantec Biosolutions:||Media contact: College Hill|
t: +423 377 7808
t: +423 377 7814
|Dr. Robert Mayer
College Hill Life Sciences
t: +49 (0)89 52 38 80 30
Pantec Biosolutions specializes in precise skin microporation technology. Our proprietary P.L.E.A.S.E.® (Precise Laser EpidermAl SystEm) technology has been developed for:
P.L.E.A.S.E.® Professional is a multi-application platform with an extendable treatment range for various applications. The platform significantly improves drug uptake in addition to reducing treatment duration, avoiding the need for injections and improving clinical outcome. The technology has significant potential to unlock a high unmet need of treatments requiring large molecular weight biopharmaceuticals.
P.L.E.A.S.E.® Professional is a state of the art bench top laser device that sets new standards for safety, precision and versatility. The advanced user interface and sophisticated software ensures convenient and simple touch-screen operation giving users the option of selecting either pre-stored parameters or customizing parameters themselves.
P.L.E.A.S.E.® Professional is developed and manufactured by Pantec Biosolutions and was awarded a red dot design award in 2010. Pantec Biosolutions is located in Ruggell, Liechtenstein.
Pantec Biosolutions’ legal disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning Pantec Biosolutions and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Pantec Biosolutions to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Pantec Biosolutions is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Pantec Biosolutions in the United States or Canada. The analytical and clinical performance characteristics of any Pantec Biosolutions product based on this technology which may be sold at some future time in the U.S. have not been established.